Enhanced Anti‐Tumour Efficacy of iRGD‐Modified Cell‐Bound Membrane Vesicles (iRGD‐CBMVs) as a Novel Drug Carrier
ABSTRACT Cancer continues to be the foremost cause of mortality in humans. Persistent challenges in cancer treatment include inadequate drug targeting, severe toxicological side effects and uncontrolled drug distribution. The bioinspired membrane vesicle drug delivery systems have been emerging as p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Journal of Extracellular Biology |
| Online Access: | https://doi.org/10.1002/jex2.70052 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849433084368257024 |
|---|---|
| author | Haonan Zhao Zhendong Huang Qinghua Sheng Wenxiang Shao Min Zeng Kun Wang Yang Zhang Ying Qin Zhihao Xiong Lizhen Chen Huaying Wang Tong Rong Zhitao Qiu Hongda Zhuang Zhiwen Wu Yuan Zhang Wendiao Zhang Yong Chen |
| author_facet | Haonan Zhao Zhendong Huang Qinghua Sheng Wenxiang Shao Min Zeng Kun Wang Yang Zhang Ying Qin Zhihao Xiong Lizhen Chen Huaying Wang Tong Rong Zhitao Qiu Hongda Zhuang Zhiwen Wu Yuan Zhang Wendiao Zhang Yong Chen |
| author_sort | Haonan Zhao |
| collection | DOAJ |
| description | ABSTRACT Cancer continues to be the foremost cause of mortality in humans. Persistent challenges in cancer treatment include inadequate drug targeting, severe toxicological side effects and uncontrolled drug distribution. The bioinspired membrane vesicle drug delivery systems have been emerging as promising therapeutic strategies. This study characterises unique cell‐bound membrane vesicles (CBMVs), which are impervious to standard cleaning agents and effectively loaded with doxorubicin (DOX). For the first time, we used iRGD peptide to modify the CBMVs to enhance the CBMVs' targeting capabilities for cancer cells. Laser confocal microscopy and 1H Nuclear Magnetic Resonance Spectra (1H NMR) have confirmed the CBMVs' iRGD modification and effective encapsulation with DOX (iRGD‐CBMVs‐DOX). Then, we used the iRGD‐CBMVs‐DOX to treat tumour cell lines and tumour‐bearing mouse models. Our research identified that iRGD‐CBMVs‐DOX proves effective in inhibiting cell growth and migration for tumour cell lines, significant anti‐tumour ability, reduced organ toxicity and continuous drug administration were revealed in tumour‐bearing mouse models. Additionally, the iRGD‐CBMVs‐DOX demonstrated sustained drug release, indicating their potential for prolonged circulation. These findings are pivotal in enhancing cancer treatment through novel nanomedicine strategies, and highlight the potential of iRGD‐modified vesicles (e.g., iRGD‐CBMVs) as efficient drug carriers, contributing to targeted and biocompatible drug delivery advancements for cancer treatment. |
| format | Article |
| id | doaj-art-8a89a57522294670a28f66f4702d6d83 |
| institution | Kabale University |
| issn | 2768-2811 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Extracellular Biology |
| spelling | doaj-art-8a89a57522294670a28f66f4702d6d832025-08-20T03:27:10ZengWileyJournal of Extracellular Biology2768-28112025-06-0146n/an/a10.1002/jex2.70052Enhanced Anti‐Tumour Efficacy of iRGD‐Modified Cell‐Bound Membrane Vesicles (iRGD‐CBMVs) as a Novel Drug CarrierHaonan Zhao0Zhendong Huang1Qinghua Sheng2Wenxiang Shao3Min Zeng4Kun Wang5Yang Zhang6Ying Qin7Zhihao Xiong8Lizhen Chen9Huaying Wang10Tong Rong11Zhitao Qiu12Hongda Zhuang13Zhiwen Wu14Yuan Zhang15Wendiao Zhang16Yong Chen17Institute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaSchool of Chinese Medicine & Life Science Jiangxi University of Chinese Medicine Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaSchool of Life Science Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaThe First Affiliated Hospital, Multi‐Omics Research Center for Brain Disorders, Clinical Research Center for Immune‐Related Encephalopathy of Hunan Province, Department of Neurology, Hengyang Medical School University of South China Hengyang Hunan ChinaInstitute for Advanced Study Nanchang University Nanchang Jiangxi ChinaABSTRACT Cancer continues to be the foremost cause of mortality in humans. Persistent challenges in cancer treatment include inadequate drug targeting, severe toxicological side effects and uncontrolled drug distribution. The bioinspired membrane vesicle drug delivery systems have been emerging as promising therapeutic strategies. This study characterises unique cell‐bound membrane vesicles (CBMVs), which are impervious to standard cleaning agents and effectively loaded with doxorubicin (DOX). For the first time, we used iRGD peptide to modify the CBMVs to enhance the CBMVs' targeting capabilities for cancer cells. Laser confocal microscopy and 1H Nuclear Magnetic Resonance Spectra (1H NMR) have confirmed the CBMVs' iRGD modification and effective encapsulation with DOX (iRGD‐CBMVs‐DOX). Then, we used the iRGD‐CBMVs‐DOX to treat tumour cell lines and tumour‐bearing mouse models. Our research identified that iRGD‐CBMVs‐DOX proves effective in inhibiting cell growth and migration for tumour cell lines, significant anti‐tumour ability, reduced organ toxicity and continuous drug administration were revealed in tumour‐bearing mouse models. Additionally, the iRGD‐CBMVs‐DOX demonstrated sustained drug release, indicating their potential for prolonged circulation. These findings are pivotal in enhancing cancer treatment through novel nanomedicine strategies, and highlight the potential of iRGD‐modified vesicles (e.g., iRGD‐CBMVs) as efficient drug carriers, contributing to targeted and biocompatible drug delivery advancements for cancer treatment.https://doi.org/10.1002/jex2.70052 |
| spellingShingle | Haonan Zhao Zhendong Huang Qinghua Sheng Wenxiang Shao Min Zeng Kun Wang Yang Zhang Ying Qin Zhihao Xiong Lizhen Chen Huaying Wang Tong Rong Zhitao Qiu Hongda Zhuang Zhiwen Wu Yuan Zhang Wendiao Zhang Yong Chen Enhanced Anti‐Tumour Efficacy of iRGD‐Modified Cell‐Bound Membrane Vesicles (iRGD‐CBMVs) as a Novel Drug Carrier Journal of Extracellular Biology |
| title | Enhanced Anti‐Tumour Efficacy of iRGD‐Modified Cell‐Bound Membrane Vesicles (iRGD‐CBMVs) as a Novel Drug Carrier |
| title_full | Enhanced Anti‐Tumour Efficacy of iRGD‐Modified Cell‐Bound Membrane Vesicles (iRGD‐CBMVs) as a Novel Drug Carrier |
| title_fullStr | Enhanced Anti‐Tumour Efficacy of iRGD‐Modified Cell‐Bound Membrane Vesicles (iRGD‐CBMVs) as a Novel Drug Carrier |
| title_full_unstemmed | Enhanced Anti‐Tumour Efficacy of iRGD‐Modified Cell‐Bound Membrane Vesicles (iRGD‐CBMVs) as a Novel Drug Carrier |
| title_short | Enhanced Anti‐Tumour Efficacy of iRGD‐Modified Cell‐Bound Membrane Vesicles (iRGD‐CBMVs) as a Novel Drug Carrier |
| title_sort | enhanced anti tumour efficacy of irgd modified cell bound membrane vesicles irgd cbmvs as a novel drug carrier |
| url | https://doi.org/10.1002/jex2.70052 |
| work_keys_str_mv | AT haonanzhao enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT zhendonghuang enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT qinghuasheng enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT wenxiangshao enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT minzeng enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT kunwang enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT yangzhang enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT yingqin enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT zhihaoxiong enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT lizhenchen enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT huayingwang enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT tongrong enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT zhitaoqiu enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT hongdazhuang enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT zhiwenwu enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT yuanzhang enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT wendiaozhang enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier AT yongchen enhancedantitumourefficacyofirgdmodifiedcellboundmembranevesiclesirgdcbmvsasanoveldrugcarrier |